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ABSTRACT OF THE THESIS 
Spatial Navigation Ability as a Predictor of Increased Clinical Impairment 
by 
Taylor Hendershott 
Master of Arts in Psychological and Brain Sciences 
Washington University in St. Louis, 2019 
Professor Denise Head, Chair 
Professor Jeffrey Zacks 
Professor Brian Carpenter 
Spatial navigation deficits are observed in Alzheimer disease (AD) cross-sectionally, but 
prediction of longitudinal clinical decline has been less examined. Cognitive mapping (CM) was 
assessed in 95 participants and route Learning (RL) was assessed in 65 participants at baseline. 
Clinical progression over an average of 4.16 years was assessed using the Clinical Dementia 
Rating scale. Relative predictive ability of these tasks was compared to episodic memory, 
hippocampal volume and cerebrospinal fluid (CSF) biomarkers (ptau181/Aβ42 ratio). CM and RL 
were significant predictors of clinical progression (ps<.032). All measures, except RL-Learning, 
remained significant predictors with episodic memory in the models (ps<.048). CM interacted 
with the hippocampus and ptau181/Aβ42 in prediction (ps<.013). CM, RL and episodic memory 
evidenced strong diagnostic accuracy (AUCs=.894, .794 and .735, respectively) with CM 
tending to perform better than episodic memory (p=.056). Taken together the results suggest that 






Chapter 1: Introduction 
There is a current research emphasis on developing cognitive measures that are sensitive to 
preclinical Alzheimer disease (AD), which is associated with an increased risk of developing 
symptomatic AD (Jack et al., 2018; Vos et al., 2013). During preclinical AD, individuals are 
clinically normal but evidence AD-related pathological changes, determined using biomarkers 
for beta-amyloid deposition and neurofibrillary tangles (Bloom et al., 2014; Jack et al., 2018; 
Price et al., 2009; Price & Morris, 1999). Thus, preclinical AD is associated with decreased 
cerebrospinal fluid (CSF) Aβ42, increased CSF phosphorylated tau (ptau181), and elevations in 
Positron Emission Tomography (PET) measures of amyloid and tau (e.g., Brier et al., 2016; Roe 
et al., 2013). Additionally, smaller brain volumes have been reported in preclinical AD, 
including smaller hippocampal volumes (Bernard et al., 2014; Storandt et al., 2009; Gordon et 
al., 2016; but see Clark et al., 2018; Schoonenboom et al., 2008). Sensitive cognitive measures 
for the preclinical phase are important for determining trajectories of cognitive decline and 
response to intervention, as future disease modifying treatments may be most effective if 
administered during the earliest stages of AD (Garcia-Alloza et al., 2009). Considering the 
expense and/or invasiveness of current methods in identifying preclinical AD (i.e., lumbar 
puncture, PET), cognitive tasks may represent an opportunity for a more accessible and lower 
risk initial screening procedure (Jack et al., 2018).  
Existing methods for delineating cognitive deficits in mild cognitive impairment (MCI) and 
symptomatic AD tend to focus on traditional psychometric measures, with an emphasis on 
episodic memory. However, these may not be sufficiently sensitive to more subtle cognitive 
difficulties present in preclinical AD (Hedden et al., 2013; Loweinstein et al., 2018; Rentz et al., 
2013). There is emerging interest in targeting spatial navigation abilities that may prove more
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 sensitive to the preclinical phase than current psychometric measures used in identifying MCI 
and symptomatic AD (Ritchie et al., 2017; Weintraub et al., 2018). The interest in spatial 
navigation is consistent with amyloid and tau deposition, as well as volumetric declines, 
occurring early in brain regions that subserve this function (e.g., hippocampus, entorhinal cortex, 
inferior parietal lobule, precuneus) (Braak et al., 2015; Coughlan et al., 2018; Storandt et al., 
2009; Thal et al., 2002). 
Deficits in multiple aspects of spatial navigation are consistently observed in MCI and 
symptomatic AD (Lithfous et al., 2013; Coughlan et al., 2018), including impairments in both 
route learning and cognitive mapping. Route learning is based on an egocentric representation 
and a sequence of body-turns in relation to environmental features. Cognitive mapping involves 
navigating based on a world-centered representation that incorporates inter-relationships 
amongst environmental features. Route learning involves striatal circuits whereas cognitive 
mapping involves hippocampal circuits (de Bruin et al., 1997; Iaria et al., 2003; O'Keefe and 
Nadel, 1978). Importantly, recent work suggests that individuals in the preclinical AD continuum 
(i.e., low CSF Aβ42,) have differential deficits in cognitive map formation relative to route 
learning (Allison et al., 2016). This cognitive mapping task demonstrated high sensitivity (92%; 
57% specificity) in detecting the preclinical AD continuum (Allison et al., 2016), was more 
sensitive than a standard episodic memory task or route learning (Allison et al., 2016), and had 
strong psychometric properties (Allison et al., accepted).  
This past work was cross-sectional and longitudinal investigations are necessary to confirm the 
utility of spatial navigation tasks for predicting clinical progression. Thus, the current study 
examined whether spatial navigation tasks were significant predictors of clinical progression
3 
 with the hypothesis that the cognitive mapping task would be a more robust predictor than route 
learning. We also examined the relative predictive ability of these tasks in comparison to 
previously reported predictors of clinical progression, including AD biomarkers (CSF 
ptau181/Aβ42 ratio), hippocampal volume and standard measures of episodic memory. Lastly, we 
examined the diagnostic accuracy of the cognitive measures.
4 
Chapter 2: Method 
 
2.1 Participants 
Participants were recruited from the Knight Alzheimer Disease Research Center (ADRC) at 
Washington University and initially participated in previous studies on spatial navigation 
(Allison et al., 2016; Allison et al., accepted). A total of ninety-eight participants completed the 
cognitive mapping (CM) task and sixty-seven completed the route learning (RL) task. Three 
individuals who completed the CM task and two individuals who completed the RL task did not 
have longitudinal data. Thus, the final sample for the current study was ninety-five for the CM 
cohort and sixty-five for the RL cohort with sixty-three individuals who completed both tasks 
(see Tables 1 and 2 for sample descriptions). Three individuals were in both initial studies; data 
from initial administration are included here. 
Participants were screened for major medical conditions, including Parkinson’s disease, 
Huntington’s disease, stroke, seizures, and major head injury. Participants had normal vision or 
wore corrective lenses. Participants consented to participation in accordance with Washington 
University Human Research Protection Office guidelines.  
2.2 Clinical Dementia Rating Scale (CDR) 
The CDR global score was used to determine the absence or presence, as well as the severity, of 
dementia (CDR of 0=clinical normality; 0.5=very mild dementia; 1= mild dementia; 2=moderate 
dementia; 3=severe dementia; Morris, 1993). Clinical diagnosis of symptomatic AD for 
individuals with a CDR>0 is made in accordance with criteria reported by the NINCDS-ADRDA 
(McKhann et al., 1984). Individuals clinically diagnosed with AD at the Knight ADRC, 
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including those meeting MCI criteria, have AD pathology in 93% of cases (Berg et al., 1998; 
Storandt et al., 2006).   
The CDR-Sum of Boxes score (CDR-SB; range: 0-18) provides a more quantitative estimate of 
clinical impairment and is based on scores in six cognitive and functional domains (memory, 
orientation, judgment and problem solving, community affairs, home and hobbies, personal care) 
used to generate the global CDR score. The larger range of CDR-SB (vs. global CDR) score 
allows for increased precision and additional information regarding cognitive impairment, 
especially for mild impairment (Lynch et al., 2006; O'Bryant et al., 2010; Williams et al., 2013). 
In the current study, clinical progression was defined as: a) an increase in global CDR score from 
the time of the spatial navigation tasks to the most recent follow-up; and b) change in CDR-SB 
across measurement occasion. CDR global scores collected between baseline and most recent 
follow-up were not used in determining clinical progression.  
2.3 Virtual Navigation Tasks 
Administration of navigation tasks are described more fully in prior work (Allison et al., 2016; 
Allison et al., accepted). The experimental maze environments consisted of a series of 
interconnected hallways with landmarks and wallpapers that differed in color. A joystick was 
used to maneuver through the environment. Participants completed both practice and a 
visuomotor expertise test in separate virtual environments.  
2.3.1 Cognitive Mapping Task 
A CM task was administered in prior studies (Allison et al., 2016; Allison et al., accepted) using 
similar procedures with differences in administration noted below. Across both studies, the task 
involved learning and retrieval phases. There were three study-test trials during the learning 
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phase. During study, participants freely explored the environment for 7 (Allison et al., 2016) or 4 
minutes (Allison et al., accepted). Participants were then given a blank 2D map of the 
environment and asked to place Xs at landmark locations. The learning score (CM-Learning) 
was the average number of landmarks correctly recalled across trials (range=0-20 for Allison et 
al., 2016; range=0-18 for Allison et al., accepted). After a 10-minute (Allison et al., 2016) or 15-
minute delay (Allison et al., accepted), participants completed 12 (Allison et al., 2016) or 6 trials 
(Allison et al., accepted) in which they were presented with a picture of a landmark and 
instructed to navigate to the landmark using the shortest path possible as quickly as possible. The 
retrieval score (CM-Retrieval) was the average amount of time taken to find each landmark. 
Because of study differences, scores on the variables within each sample were standardized (z-
transformed) to obtain an estimate of each individual’s relative ranking. 
2.3.2 Route Learning Task 
The RL task included both learning and delayed retrieval phases (Allison et al. 2016). During the 
learning phase, participants followed the same route marked by arrows repeatedly for 5 minutes. 
Next, participants drew the learned path on a blank 2D map of the environment. The study-test 
trials were completed four times. The learning score (RL-Learning) was the average proportion 
of correctly drawn turns at intersections relative to the total number of intersections along the 
route over the four trials (range=0-1). After a 10-minute delay, participants traversed the 
designated route without arrows three times. The average amount of time taken to traverse the 
route across trials was the retrieval phase variable (RL-Retrieval). 
2.4 Episodic Memory Composite Score 
A memory composite was created using free recall from the Selective Reminding Task (Grober 
et al. 1988), immediate and delayed recall on the Logical Memory Test from the Wechsler 
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Memory Scale (Wechsler & Stone, 1973) or Wechsler Memory Scale-III (Wechsler, 1997), and 
total score on the Associate Learning Task from the Wechsler Memory Scale (Wechsler & 
Stone, 1973) or Wechsler Memory Scale-III (Wechsler, 1997). All test scores were standardized 
(z-scored); standardized scores for each participant were averaged to create the composite score. 
In the case of multiple versions of a test, raw scores from each subsample were standardized 
separately and then combined across data sets.  
2.5 CSF Collection and Processing   
CSF collection has been previously described (Fagan et al., 2006). All CSF samples were 
analyzed using next generation Elecsys electrochemiluminescent immunoassays for Aβ42 and 
ptau181 developed by Roche Diagnostics (Basel, Switzerland) and run on the automated Roche 
Cobas e 601 analyzer (Bittner, Zetterberg et al., 2016). Values for Aβ42 above 1,700 pg/ml have 
not been validated and are not to be used in clinical decision making. The ratio between ptau181 
and Aβ42 was used as the AD biomarker measure because it has been found to best map onto 
PET imaging results (Schindler et al., 2018). 
2.6 Structural MRI Acquisition and Processing  
MRI scans were acquired using one of two Siemens 3T scanners (TIM Trio: TE=3ms, 
TR=2400ms, TI=1000ms, FA=8°, 256x256 mm acquisition matrix, 1x1x1mm voxels; BioGraph 
scanner: TE=2.95ms, TR=2300ms, TI=900ms, FA=9°, 240x256 mm acquisition matrix, 
1x1x1.2mm voxels). The FreeSurfer image analysis suite v5.3 was used for image processing 
and delineation of regions of interest (Fischl et al., 2002). FreeSurfer implements an automated 
probabilistic labeling procedure where individual voxels in an image are assigned to a 
neuroanatomical label based on data from a manually labeled training set. Volumetric data 
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obtained through this procedure are highly correlated with manually generated volumes (Desikan 
et al., 2006; Fischl et al., 2002). The hippocampus was the region-of-interest for the current 
study. Volumes were summed across hemispheres and estimated intracranial volume was used to 
adjust volumes for body size differences using an analysis of covariance approach (Buckner et 
al., 2004).  
2.7 Computer Experience   
Using a Likert scale (0-7), participants self-reported their experience with computers, computer 
games and virtual reality games. A measure of total computer experience was created from the 
sum of experience scores (0-21). 
2.8 Health Composite   
A health composite (0-5) was created using the sum of past or present mild head trauma, heart 
problems, hypertension, diabetes and depression.  
2.9 Statistical Analyses  
2.9.1 General 
CM-Learning, CM-Retrieval, RL-Learning and RL-Retrieval variables were examined in 
separate models. When a spatial navigation variable was a significant predictor, previously 
established predictors were added to the model to assess whether there was unique variance 
explained by the spatial navigation variable. Established predictors (CSF ptau181/Aβ42, 
hippocampal volume or episodic memory composite) were examined in separate models. Age, 
sex, education and the health composite were covariates in all analyses. For logistic and linear 
mixed effects models, the learning variables were reverse scored so that higher scores reflected 
worse performance. Standardized variables were used in all analyses.  
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2.9.2 CDR Progression 
Logistic regression analyses were conducted using IBM SPSS Statistics 25. These analyses were 
used to determine whether baseline spatial navigation performance predicted global CDR 
progression (1=progression; 0=no-progression). Only episodic memory was additionally 
examined in these models considering the sample size issues with a categorical outcome.  
2.9.3 Longitudinal Change in CDR-SB 
Linear mixed effects models were used to determine whether spatial navigation performance 
predicted change in CDR-SB over time. These models were conducted using the nlme package 
(Pinheiro et al., 2018) in R version 3.5.1 (RStudio Team, 2005). Time (years in study) and 
intercept were random effects. The interaction between the spatial navigation variables and time 
were the independent variables of primary interest. In models examining relative predictive 
utility, the other predictor variable (i.e., CSF ptau181/Aβ42, hippocampal volume, episodic 
memory) and their interaction with time were added to the model. Finally, three-way interactions 
between CM variables, CSF ptau181/Aβ42 or hippocampal volume, and time were included in a 
model to examine whether there was moderation of any relationship observed between CM 
performance and CDR-SB progression. Three-way interactions were not conducted for RL 
variables due to the smaller sample size.   
Due to the heterogeneous baseline CDR status of participants (CDR=0-1), CM models predicting 
CDR-SB progression including only participants with CDR=0 at baseline (n=81) were examined 
in order to assess whether CM task performance may be a sensitive marker of the preclinical 
disease stage (see Tables 3 for sample description). These analyses were not conducted in the RL 




2.9.4 Diagnostic Accuracy 
Receiver operating characteristic (ROC) analyses were conducted to assess diagnostic accuracy 
in predicting clinical progression according to global CDR for the sixty-three participants who 
completed CM, RL and episodic memory tasks. For these analyses, standardized composites 
were created combining the learning and retrieval phases within each task. In addition, the area 
under the curve (AUC) values were compared amongst the CM, RL and episodic memory 
composites using the method of DeLong, DeLong and Clarke-Pearson (1998) with the paired 
data option.  
2.9.5 Outliers 
Outliers were defined as values >3 STD from the group mean. All analyses were conducted with 












Chapter 3: Results 
 
3.1 Cognitive Mapping: Global CDR Progression 
CM-Learning (OR=3.131, CI=1.376-7.123, p=.007) and CM-Retrieval (OR=2.950, 
CI=1.444-6.024, p=.003) significantly predicted clinical progression. These relationships 
remained with episodic memory added to the respective models (CM-Learning: OR=2.591, 
CI=1.007-6.667, p=.048; CM-Retrieval: OR=2.409, CI=1.104-5.257, p=.027). See 
Supplementary Table 1 for full regression results. 
3.2 Cognitive Mapping: Longitudinal Change in CDR-SB  
CM-Learning (β=.266, p<.001) and CM-Retrieval (β=.250, p=.002) significantly predicted 
clinical progression (Figure 1; Supplementary Tables 2, 3, 4). These relationships remained with 
episodic memory (CM-Learning: β=.216, p=.003; CM-Retrieval: β=.184, p=.021) and 
hippocampal volume (CM-Learning: β=.236, p=.004; CM-Retrieval: β=.233, p=.033) added to 
the respective models. Neither CM-Learning (β=.122, p=.197) nor CM-Retrieval (β=.123, 
p=.369) remained a significant predictor of clinical progression with ptau181/Aβ42 added to the 
respective models.  
Hippocampal volume significantly moderated the association of CM-Learning (β=-.276, p<.001) 
and CM-Retrieval (β=-.270, p=.002) with longitudinal CDR-SB progression (Figure 2). When 
outliers were removed, the ptau181/Aβ42 ratio also significantly moderated the association of CM-
Learning (without outliers: β=.309, p=.001; with outliers: β=.110, p=.194) and CM-Retrieval 




3.3 Cognitive Mapping: Longitudinal Change in CDR-SB 
with Global CDR=0 at Baseline 
In this clinically normal at baseline sample, CM-Learning (β=.155, p=.024) was a significant 
predictor of clinical progression (Supplementary Table 5). This remained true when episodic 
memory (β=.151, p=.032) was added to the model. This relationship was no longer significant 
when ptau181/Aβ42 (β=.105, p=.222) or hippocampal volume (β=.101, p=.206) were added to the 
models. CM-Retrieval (β=.121, p=.196) was not a significant predictor of clinical progression in 
this sample (Supplementary Table 6).  
3.4 Route Learning: Global CDR Progression 
RL-Learning (OR=3.293, CI=1.307-8.298, p=.011) and RL-Retrieval (OR=6.301, CI=1.941-
20.461, p=.002) significantly predicted clinical progression (Supplementary Table 7). RL-
Retrieval remained a significant predictor when episodic memory was added to the model 
(OR=4.781, CI=1.341-17.045, p=.016), but RL-Learning did not (OR=1.911, CI=.631-5.792, 
p=.252). 
3.5 Route Learning: Longitudinal Change in CDR-SB 
RL-Learning (β=.202, p=.032) and RL-Retrieval (β=.467, p<.001) significantly predicted CDR-
SB progression (Figure 1; Supplementary Tables 8 and 9). RL-Learning did not remain a unique 
predictor in models with episodic memory (β=.015, p=.886), hippocampus (β=.040, p=.714) or 
ptau181/Aβ42 (β=.143, p=.086). Conversely, RL-Retrieval remained a significant predictor of 
CDR-SB progression when episodic memory (β=.377, p<.001), hippocampus (b=.464, p<.001) 
or ptau181/Aβ42 (β=.482, p<.001) were added to the model. 
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3.6 Diagnostic Accuracy 
The AUCs for CM, RL and episodic memory were all significant (Figure 3; Table 4). The AUCs 
for CM and RL were not significantly different (χ2=1.59, p=.207). The AUC for RL was not 
significantly different than the AUC for episodic memory (χ2=.91, p=.339). There was a non-






Chapter 4: Discussion 
 
This longitudinal study examined whether tasks assessing the ability to form, retain and use a 
cognitive map or the ability to learn and retrieve a novel route predicted clinical progression. 
While a previous cross-sectional investigation observed a significant deficit in CM, but not RL, 
in individuals in the preclinical AD continuum (Allison et al., 2016), the current results indicated 
that both CM and RL were significant predictors of global CDR and CDR-SB progression. 
Furthermore, the prior work (Allison et al., 2016) found that the CM task evidenced significantly 
greater diagnostic accuracy than RL, whereas there was not a significant difference between the 
tasks in the current study. The differences across studies could in part relate to the inclusion of 
individuals with symptomatic AD in the present study as deficits in both CM and RL were 
observed in symptomatic AD at baseline (Allison et al., 2016; for reviews, see Coughlan et al., 
2018; Lithfous et al., 2013). Thus, although CM tasks may be preferable for detecting preclinical 
AD cross-sectionally, when examining clinical progression using a group of individuals with 
varying levels of cognitive impairment (i.e., from clinical normality to symptomatic AD), 
baseline performance on either CM or RL tasks may serve to predict later progression of the 
disease.  
Our findings are generally consistent with prior investigations examining the ability of spatial 
navigation tasks to predict clinical progression in clinically normal individuals, as well as those 
with MCI and symptomatic AD (Serino, Morganti, Colombo, & Riva, 2018; Verghese, Lipton, 
& Ayers, 2017; Wood et al., 2016; but see Weniger et al., 2011). Of note, these previous studies 
mainly utilized CM tasks for assessing spatial navigation, whereas the current study examined 
the ability of both CM and RL to predict progression. Not only did our tasks predict clinical 
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progression, but CM-Learning, CM-Retrieval and RL-Retrieval all predicted clinical progression 
with episodic memory included in the models. There was also a strong trend for overall CM 
performance to demonstrate greater diagnostic accuracy for CDR progression compared to 
episodic memory, which is consistent with prior findings demonstrating that CM was better than 
episodic memory at discriminating clinically normal from preclinical AD continuum individuals 
cross-sectionally (Allison et al., 2016). Additionally, when examining models only containing 
participants with CDR=0 at baseline, CM-Learning remained a significant predictor of clinical 
progression. Importantly, when episodic memory was added to this model, CM-Learning 
remained a significant predictor of clinical progression, but episodic memory did not. These 
findings together suggest that relative to standard psychometric tasks of memory, spatial 
navigation tasks, particularly CM tasks, could be useful indicators for risk of clinical 
progression, including during the preclinical phase.  
While the CM task was a significant predictor of CDR-SB progression when hippocampal 
volume was added to the models, the CM task was not a unique predictor with CSF ptau181/Aβ42 
in the models. Both measures interacted with hippocampal volume and with CSF ptau181/Aβ42 in 
predicting progression. Thus, individuals with deficits in CM, in addition to elevated AD 
pathology or reduced hippocampal volume, evidenced the greatest degree of clinical progression. 
In contrast, having only elevated AD pathology, reduced hippocampal volume or lower CM 
performance were each associated with slower progression over time. Thus, not only may CM 
measures be useful in prediction in isolation, but they may have added value when used in 
conjunction with hippocampal volume and/or AD biomarkers. 
Regarding RL, retrieval phase performance did provide unique predictive value relative to 
hippocampal volume or CSF ptau181/Aβ42. Furthermore, it was a significant predictor of CDR-
16 
 
SB progression, whereas episodic memory was not significant when both were in the same 
model. However, the learning phase was not a unique predictor in any of the models with the 
previously established predictors. There was some indication of a ceiling effect during the 
learning phase, which may have limited it as a predictor relative to other measures (20% with a 
score above 96%). Importantly, overall RL performance did not evidence significantly greater 
diagnostic accuracy compared to the episodic memory composite. The latter finding in particular 
does place limits on the utility of the current RL task compared to the CM task in predicting 
clinical progression. Furthermore, the psychometric properties of RL have yet to be established, 
whereas recent work has established strong psychometric properties of CM (Allison et al., 
accepted). 
Limitations of this study include that there was an insufficient number of clinically normal 
individuals who converted to AD over the course of the study to fully examine whether spatial 
navigation measures predict conversion (i.e., n=7 of 81 for CM; n=6 of 50 for RL). In addition, 
the smaller size of the samples with both RL and either CSF or MRI precluded robust estimation 
of the 3-way interactions with time. Lastly, the sample consisted of highly educated individuals, 
which limits the generalizability of the results. 
Collectively, current findings indicate that baseline CM and RL performance were associated 
with future clinical progression. These findings highlight the potential utility of spatial 
navigation tasks as assessment tools for identifying risk of progression to more advanced stages 
of dementia. Measures of CM may be particularly useful considering the evidence that these may 
be more powerful than standard episodic memory measures. Future work should examine 
whether the spatial navigation tasks predict conversion from the preclinical AD phase to 
symptomatic AD with a sufficiently large sample of converters. In addition, longitudinal 
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investigations of spatial navigation performance would be important in order to determine 
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Tables and Figures 
 
Table 1. Sample characteristics: cognitive mapping task 
Notes. CDR=Clinical Dementia Rating scale; m=mean; sd=standard deviation. Time in 
study=years between baseline assessment and most recent CDR. At baseline, 81 participants 
were CDR=0, 10 were CDR=0.5, and 4 were CDR=1. Among the 17 decliners, 7 went from 
CDR=0 to CDR>0, 6 went from CDR=0.5 to CDR=1, 1 went from CDR=0.5 to CDR=2, 3 went 
from CDR=1 to CDR=2; *p<.05 difference between no progression and yes progression groups. 
N=67 from Allison et al., 2016; N=28 from Allison et al., accepted). Participants had CSF 
(M=.87, range=-1.97-1.68) and MRI (M=.90, range=-2.00-1.99) collection within 2 years of the 






Total Sample No Progression  Yes Progression  
N 95 78 17 
Gender (M/F) 49/46 39/39 10/7 
Age (years) (M, SD)* 72.10 (8.40) 70.60 (7.86) 78.94 (7.52) 
Age range 50-90 50-85 66-90 
Education (years) (M, SD) 16.57 (2.38) 16.40 (2.44) 17.19 (2.07) 
Education (range) 12-21 12-21 13-20 
Health Composite (M, SD)* .77 (.82) .67 (.77) 1.24 (.90) 
Time in study (years) (M, SD) 4.16 (1.84) 4.11 (1.86) 4.04 (1.83) 
Time in study (range) 1.02-7.07 1.19-7.07 1.02-7.02 
Number CDR follow ups (M, SD) 4.40 (1.84) 4.35 (1.97) 5.00 (1.84) 
Number CDR follow ups (range) 2-8 2-8 2-8 
Episodic Memory (M, SD) .04 (.86) .13 (.69) -.65 (1.09) 
Hippocampus (cm3) (N, M, SD)  74; 739 (111) 64; 759 (97) 10; 613 (114) 
ptau181/Aβ42 (N, M, SD) 64; .026 (.022) 57; .023 (.019)  7; .049 (.031)  
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Table 2. Sample characteristics: route learning task 
 
 
Notes. CDR=Clinical Dementia Rating Scale; M=mean; SD=standard deviation. Time in 
study=years between baseline assessment and most recent CDR. At baseline, 50 participants 
were CDR=0, 10 were CDR=0.5, and 5 were CDR=1. Among the 17 decliners, 6 went from 
CDR=0 to CDR>0, 6 went from CDR=0.5 to CDR=1, 1 went from CDR=.5 to CDR=2, 4 went 
from CDR=1 to CDR=2; *p<.05 difference between no progression and yes progression groups. 
N=65 from Allison et al., 2016). Participants had CSF (M=.72, range=-1.97-1.66) and MRI 
(M=.90, range=-2.15-2.03) collection within 2.15 years of the route learning condition and 








Total Sample No Progression  Yes Progression  
N 65 48 17 
Gender (M/F) 32/33 21/27 11/6 
Age (years) (M, SD)* 71.98 (9.35) 69.60 (8.82) 78.71 (7.48) 
Age (range) 50-90 50-85 66-90 
Education (years) (M, SD) 16.35 (2.38) 16.04 (2.41) 17.31 (2.09) 
Education range 12-20 12-20 12-20 
Health Composite (M, SD)* .85 (.85) .69 (.80) 1.29 (.85) 
Time in study (years) (M, SD)* 4.95 (1.60) 5.26 (1.37) 4.06 (1.91) 
Time in study (range) 1.02-7.07 1.19-7.07 1.02-7.07 
Number CDR follow ups (M, SD) 5.00 (1.83) 5.19 (1.72) 4.47 (2.07) 
Number CDR follow ups (range) 2-8 2-8 2-8 
Episodic Memory (M, SD)* -.03 (.88) .19 (.72) -.65 (.99) 
Hippocampus (cm3) (N, M, SD)*  49; 725 (131) 38; 763 (106) 11; 593 (127) 
ptau181/Aβ42 ratio (N, M, SD) 41; .023 (.018) 34; .018 (.011) 7; .044 (.028) 
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Table 3. Sample characteristics: cognitive mapping task with CDR=0 at baseline 
Notes. CDR=Clinical Dementia Rating scale; m=mean; sd=standard deviation. Time in 
study=years between baseline assessment and most recent CDR. Among the 7 converters, 2 went 
from CDR=0 to CDR=.5, 3 went from CDR=0 to CDR=1, and 2 went from CDR=0 to CDR=2; 
*p<.05 difference between no conversion and yes conversion groups. N=53 from Allison et al., 
2016; N=28 from Allison et al., accepted). Participants had CSF (M=.87, range=-1.97-1.68) and 
MRI (M=.92, range=-2.00-1.99) collection within 2 years of the cognitive mapping condition 










Total Sample No Conversion  Yes Conversion  
N 81 74 7 
Gender (M/F) 40/41 37/37 3/4 
Age (years) (M, SD)* 71.11 (7.73) 70.43 (7.59) 78.29 (5.47) 
Age range 50-84 50-84 70-84 
Education (years) (M, SD) 16.59 (2.40) 16.53 (2.41) 17.21 (2.38) 
Education (range) 12-21 12-21 13-20 
Health Composite (M, SD)* .72 (.81) .65 (.77) 1.43 (.98) 
Time in study (years) (M, SD) 4.35 (1.84)  4.24(1.85) 5.48 (1.49) 
Time in study (range) 1.33-7.07 1.33-7.07 3.05-7.02 
Number CDR follow ups (M, SD) 4.54 (1.86) 4.45 (1.81) 5.57 (2.23) 
Number CDR follow ups (range) 2-8 2-8 2-8 
Episodic Memory (M, SD) -.18 (.63) -.20 (.60) .01 (.89) 
Hippocampus (cm3) (N, M, SD)  68; 756 (92) 63; 760 (87) 5; 711 (138) 
ptau181/Aβ42 (N, M, SD) 62; .025 (.02) 57; .023 (.019)  5; .046 (.030)  
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Table 4. ROC analyses 
 Cognitive Mapping Route Learning Memory 
AUC (SE) .894 (.041) .794 (.067) .735 (.080) 
p-value <.001 .001 .006 
Youden Index .687 .517 .496 
Sensitivity 1.00 .600 .600 
Specificity .687 .917 .896 















































































































 Odds Ratio 95% CI p 
Base Model 
Age 3.799 1.435-10.059 .007 
Gender 1.187 .281-5.009 .815 
Education 1.590 .761-3.321 .217 
Health 1.458 .784-2.712 .234 
CM-Learning 3.131 1.376-7.123 .007 
    
Episodic Memory Model 
Age 4.177 1.278-13.658 .018 
Gender 2.925 .490-17.473 .239 
Education 1.988 .803-4.921 .137 
Health 1.771 .820-3.824 .146 
CM-Learning 2.591 1.007-6.667 .048 
Memory 3.555 1.535-8.233 .003 
    
Base Model 
Age 5.297 1.690-16.603 .004 
Gender 1.944 .440-8.590 .380 
Education 2.136 .936-4.872 .071 
Health 1.624 .861-3.063 .134 
CM-Retrieval 2.950 1.444-6.024 .003 
    
Episodic Memory Model 
Age 5.191 1.464-18.411 .011 
Gender 4.511 .703-28.964 .112 
Education 2.730 .998-7.465 .050 
Health 2.110 .975-4.565 .058 
CM-Retrieval 2.409 1.104-5.257 .027 
Memory 3.535 1.499-8.332 <.001 
33 
 
Supplementary Table 2. Linear mixed model results: cognitive mapping - learning phase 
 Beta t p 
Base Model 
Age .491 2.276 .025 
Gender -.146 -.383 .703 
Education -.146 -.768 .444 
Health -.304 -1.504 .136 
Time .290 4.125 <.001 
CM-Learning .260 1.296 .198 
Time x CM-Learning .266 3.635 <.001 
    
CSF ptau181/Aβ42 Ratio Model 
Age .129 .730 .468 
Gender -.208 -.764 .448 
Education .075 .580 .564 
Health -.105 -.683 .497 
Time .220 2.774 .006 
CM-Learning -.077 -.408 .685 
ptau181/Aβ42 -.054 -.315 .754 
CM-Learning x ptau181/Aβ42 -.102 -.697 .489 
Time x CM-Learning .122 1.296 .197 
Time x ptau181/Aβ42 .281 3.186 .002 
Time x ptau181/ Aβ42 x CM-Learning .110 1.304 .194 
    
Hippocampal Volume Model 
Age .047 .240 .811 
Gender -.319 -1.210 .231 
Education -.023 -.175 .861 
Health -.037 -.274 .785 
Time .237 3.393 <.001 
CM-Learning -.092 -.552 .583 
Hippocampus -.448 -2.719 .008 
CM-Learning x Hippocampus -.034 -.220 .826 
Time x CM- Learning .236 2.963 .004 
Time x Hippocampus -.335 -4.687 <.001 
Time x Hippocampus x CM-Learning -.276 -4.185 <.001 
    
Episodic Memory Model 
Age .566 3.084 .003 
Gender .485 1.440 .154 
Education -.051 -.313 .755 
Health -.102 -.595 .554 
Time .280 4.166 <.001 
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CM-Learning -.087 -.473 .637 
Memory 1.158 5.710 <.001 
Time x CM-Learning .216 2.982 .003 




Supplementary Table 3. Linear mixed model results: cognitive mapping - retrieval phase 
 Beta t p 
Base Model 
Age .474 2.472 .015 
Gender .092 .267 .790 
Education -.078 -.469 .640 
Health -.265 -1.480 .143 
Time .290 4.042 <.001 
CM-Retrieval .793 4.582 <.001 
Time x CM- Retrieval .250 3.215 .002 
    
CSF ptau181/Aβ42 Ratio Model 
Age .152 .864 .392 
Gender -.249 -.894 .375 
Education .086 .675 .502 
Health -.080 -.529 .599 
Time .193 2.147 .033 
CM- Retrieval -.027 -.110 .913 
ptau181/Aβ42 -.169 -.778 .440 
ptau181/Aβ42 x CM-Retrieval .059 .246 .807 
Time x CM-Retrieval .123 .901 .369 
Time x ptau181/Aβ42 .240 2.120 .036 
Time x ptau181/Aβ42 x CM-Retrieval .176 1.316 .190 
    
Hippocampal Volume Model 
Age .110 .630 .531 
Gender -.268 -1.145 .256 
Education .006 .052 .959 
Health -.042 -.357 .722 
Time .194 2.550 .012 
CM-Retrieval .106 .573 .569 
Hippocampus -.371 -2.323 .023 
CM-Retrieval x Hippocampus -.360 -2.164 .034 
Time x CM-Retrieval .233 2.150 .033 
Time x Hippocampus -.277 -3.541 <.001 
Time x Hippocampus x CM-
Retrieval -.270 -3.118 .002 
    
Episodic Memory Model 
Age .517 3.140 .002 
Gender .605 1.995 .049 
Education -.028 -.197 .845 
Health -.089 -.575 .567 
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Time .281 4.075 <.001 
CM- Retrieval .525 3.116 .003 
Memory .947 4.892 <.001 
Time x CM-Retrieval .184 2.320 .021 





Supplementary Table 4. Linear mixed model results: cognitive mapping –  
ptau181/Aβ42 without outliers 
 Beta t p 
CSF ptau181/Aβ42 Ratio Model – CM-Learning 
Age .127 .724 .472 
Gender -.158 -.576 .567 
Education .044 .332 .741 
Health -.091 -.590 .557 
Time .212 2.895 .004 
CM-Learning -.054 -.279 .781 
ptau181/Aβ42 -.070 -.404 .688 
ptau181/Aβ42 x CM-Learning -.116 -.564 .575 
Time x CM-Learning .145 1.672 .097 
Time x ptau181/Aβ42 .324 3.957 <.001 
Time x ptau181/Aβ42 x CM-Learning .309 3.322 .001 
    
CSF ptau181/Aβ42 Ratio Model – CM-Retrieval 
Age  .152 .876 .385 
Gender -.188 -.672 .505 
Education .080 .632 .530 
Health -.010 -.065 .948 
Time .176 2.052 .042 
CM-Retrieval -.012 -.048 .962 
ptau181/Aβ42 -.170 -.767 .446 
ptau181/Aβ42 x CM-Retrieval .088 .312 .756 
Time x CM-Retrieval .165 1.259 .210 
Time x ptau181/Aβ42 .248 2.310 .022 




Supplementary Table 5. Linear mixed model results: CDR=0 at baseline, CM-Learning  
 Beta t p 
Base Model 
Age .094 1.393 .168 
Gender .036 .405 .687 
Education -.074 -1.711 .091 
Health -.094 -2.039 .045 
Time .164 2.635 .009 
CM-Learning -.103 -1.204 .233 
Time x CM-Learning .155 2.275 .024 
    
CSF ptau181/ Aβ42 Ratio Model 
Age .058 .697 .489 
Gender .025 .243 .809 
Education -.078 -1.581 .120 
Health -.115 -1.977 .053 
Time .198 2.729 .007 
CM-Learning -.103 -.920 .362 
ptau181/Aβ42 -.125 -1.247 .218 
Time x CM-Learning .105 1.226 .222 
Time x ptau181/Aβ42 .244 2.930 .004 
    
Hippocampal Volume Model 
Age .084 1.007 .318 
Gender .050 .507 .614 
Education -.096 -1.874 .066 
Health -.101 -1.951 .056 
Time .180 2.538 .012 
CM-Learning -.046 -.447 .657 
Hippocampus .163 1.445 .154 
Time x CM-Learning .101 1.270 .206 
Time x Hippocampus -.185 -2.263 .025 
    
Episodic Memory Model 
Age .106 1.579 .119 
Gender .076 .825 .412 
Education -.076 -1.754 .084 
Health -.083 -1.806 .075 
Time .169 2.607 .010 
CM-Learning -.117 -1.313 .193 
Memory .082 .633 .529 
Time x CM-Learning .151 2.165 .032 
Time x CM-Memory .026 .263 .793 
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Supplementary Table 6. Linear mixed model results: CDR=0 at baseline, CM-Retrieval 
 Beta t p 
Base Model 
Age .098 1.502 .137 
Gender .063 .732 .467 
Education -.070 -1.702 .093 
Health -.086 -1.934 .057 
Time .165 2.491 .014 
CM-Retrieval -.007 -.059 .953 
Time x CM- Retrieval .121 1.298 .196 





































Supplementary Table 7. Logistic regression results: route learning task 
 Odds Ratio 95% CI p 
Base Model 
Age 5.439 1.705-17.349 .004 
Gender 1.389 .266-7.258 .697 
Education 2.578 1.072-6.204 .034 
Health 1.439 .666-3.109 .355 
RL-Learning 3.293 1.307-8.298 .011 
    
Episodic Memory Model 
Age 5.101 1.401-18.571 .013 
Gender 5.015 .535-46.987 .158 
Education 3.536 1.247-10.029 .018 
Health 1.904 .754-4.803 .173 
RL-Learning 1.911 .631-5.792 .252 
Memory 4.104 1.223-13.772 .022 
    
Base Model 
Age 9.614 1.965-47.040 .005 
Gender 1.557 .246-9.875 .638 
Education 3.677 1.157-11.682 .027 
Health 1.762 .673-4.612 .249 
RL-Retrieval 6.301 1.941-20.461 .002 
    
Episodic Memory Model 
Age 12.684 1.892-85.018 .009 
Gender 7.632 .474-123.011 .152 
Education 4.862 1.398-16.909 .013 
Health 2.399 .748-7.699 .141 
RL-Retrieval 4.781 1.341-17.045 .016 
















Supplementary Table 8. Linear mixed model results: route learning – learning phase 
 Beta t p 
Base Model 
Age .671 2.303 .025 
Gender -.378 -.759 .451 
Education -.274 -1.167 .248 
Health -.652 -2.401 .020 
Time .387 4.228 <.001 
RL-Learning .602 2.356 .022 
Time x RL-Learning .202 2.159 .032 
    
CSF ptau181/Aβ42 Ratio Model 
Age .049 .184 .855 
Gender -.406 -1.069 .293 
Education .113 .616 .542 
Health -.205 -.910 .369 
Time .264 3.465 <.001 
RL-Learning .398 1.912 .064 
ptau181/Aβ42 -.139 -.690 .495 
Time x RL-Learning .143 1.730 .086 
Time x ptau181/Aβ42 .408 5.229 <.001 
    
Hippocampal Volume Model 
Age -.123 -.429 .670 
Gender -.478 -1.222 .228 
Education -.141 -.737 .465 
Health -.397 -1.835 .074 
Time .354 3.779 <.001 
RL-Learning .374 1.775 .083 
Hippocampus -.837 -3.265 .002 
Time x RL-Learning .040 .367 .714 
Time x Hippocampus -.464 -4.108 <.001 
    
Episodic Memory Model 
Age .774 3.158 .003 
Gender .556 1.192 .238 
Education -.115 -.573 .569 
Health -.402 -1.728 .089 
Time .370 4.353 <.001 
RL-Learning -.205 -.828 .411 
Memory -1.719 -5.695 <.001 
Time x RL-Learning .015 .143 .886 
Time x Memory .388 2.993 .0031 
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Supplementary Table 9. Linear mixed model results: route learning – retrieval phase 
 Beta t p 
Base Model 
Age .975 3.623 <.001 
Gender -.489 -1.022 .311 
Education -.193 -.857 .395 
Health -.670 -2.569 .013 
Time .382 5.182 <.001 
RL-Retrieval 1.004 4.142 <.001 
Time x RL-Retrieval .467 5.230 <.001 
    
CSF ptau181/Aβ42 Ratio Model 
Age -.020 -.071 .944 
Gender -.335 -.804 .427 
Education .143 .735 .467 
Health -.219 -.905 .372 
Time .346 4.890 <.001 
RL-Retrieval .075 .197 .845 
ptau181/Aβ42 -.067 -.321 .750 
Time x RL-Retrieval .482 4.033 <.001 
Time x ptau181/Aβ42 .374 5.444 <.001 
    
Hippocampal Volume Model 
Age -.117 -.402 .690 
Gender -.635 -1.602 .117 
Education -.134 -.686 .497 
Health -.440 -1.967 .056 
Time .383 4.708 <.001 
RL-Retrieval .284 1.014 .316 
Hippocampus -.901 -3.363 .002 
Time x RL-Retrieval .464 3.737 <.001 
Time x Hippocampus -.286 -2.830 .005 
    
Episodic Memory Model 
Age .951 4.027 <.002 
Gender .358 .779 .439 
Education -.088 -.445 .658 
Health -.440 -1.900 .063 
Time .376 5.120 <.001 
RL-Retrieval .443 1.741 .087 
Memory 1.253 4.311 <.001 
Time x RL-Retrieval .377 3.693 <.001 
Time x RL-Memory .166 1.593 .113 
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